Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0941820160260040269
Korean Journal of Clinical Pharmacy
2016 Volume.26 No. 4 p.269 ~ p.282
Novel Oral Anticoagulants for the Treatment of Venous Thromboembolism in Cancer Patients
Kim Joo-Hee

Kwak Hye-Seon
Abstract
Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism, has increased in cancer patients and adversely affects their prognosis. Low-molecular-weight heparins are recommended as efficacious and safe anticoagulation treatment in cancer patients. However, in practice, oral anticoagulation is preferred, especially if longterm or extended treatment is necessary. Novel oral anticoagulants have recently emerged as an alternative to the standard therapy owing to the ease of administration, predictable anticoagulation effect without the need of laboratory monitoring, and fewer drug interactions. These new agents have been shown as effective and safe for the management of cancer-associated thrombosis in ongoing head-to-head comparative trials. Here we review the advances and limitation of current anticoagulant therapies.
KEYWORD
Novel oral anticoagulant , cancer , venous thromboembolism
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)